A Message from Our Friends at Army of Women…

Endocrine therapies, such as Nolvadex (tamoxifen), Arimidex (anastrazole), Aromasin (exemestane), or Femara (letrozole), are medications for breast cancer that block or remove hormones. Endocrine therapies can improve survival in women whose cancer has estrogen receptors (ER+). Research shows that some women take their endocrine therapies very regularly, whereas others do not take it regularly, stop taking it, or switch to another endocrine medication. It is important to understand the factors that contribute to these patterns of medication adherence, so that programs can be developed to inform women who are starting endocrine therapy.

If you’ve been diagnosed with breast cancer and are now taking, or have taken within the past 12 months, one of the following pill-type medications: Nolvadex (tamoxifen), Arimidex (anastrazole), Aromasin (exemestane), or Femara (letrozole), please read about this study and consider signing up. Whether or not it’s right for you, please pass it along to any friend who you think might want to take part.

What’s the study about?

In an effort to find the best way to help medical personnel and women diagnosed with breast cancer, researchers have developed an online survey to understand women’s thoughts, feelings, and behaviors relevant to taking endocrine therapies. You don’t have to leave your house to participate! Five hundred women are needed for this study.

What’s involved?

If you join this study, you will be directed to an anonymous online survey, which will take approximately 30 minutes to complete. Questions ask about your thoughts, feelings, and behaviors relevant to taking endocrine therapies.

Who is conducting the study?

Annette Stanton, PhD, University of California Los Angeles and Ann Partridge, MD, MPH, Dana-Farber Cancer Institute, Boston

Where?

Anywhere in the United States

Who can participate?

You can join the Endocrine-ABC study if you match ALL of these criteria:

• You are a woman who was diagnosed with breast cancer

• You are now taking, or have taken within the past 12 months, one of the following pill-type medications: Nolvadex (tamoxifen), Arimidex (anastrazole), Aromasin (exemestane), or Femara (letrozole)

• You have access to the Internet and are willing to complete an online survey

• You live in the United States

The researchers are interested in the experiences of ALL women, including those women who do or do not regularly take their medication, those who stop their prescription before the date recommended by their physician, and those who switch from one endocrine medication to another.